Navigation Links
Cystic fibrosis disrupts pancreas two ways in CF-related diabetes
Date:9/17/2012

A new University of Iowa study suggests there are two root causes of a type of diabetes associated with cystic fibrosis (CF). The findings, which already have sparked a clinical trial, may guide development of new treatments or even help prevent diabetes in patients with CF.

Almost half of patients with CF will develop diabetes by age 30 and almost one quarter will develop it in their teens. In addition to the health problems caused by high blood sugar, diabetes also worsens lung disease and increases the risk of dying for people with CF. However, the underlying cause of CF-related diabetes is not well understood, and differs from the causes of type 1 or type 2 diabetes.

Using a new animal model of CF, the study found two abnormalities that affect the pancreas, the organ that produces insulin, which controls blood sugar levels. The study shows that CF progressively damages the pancreas, disrupting insulin production. More surprisingly, the study also found that CF disrupts the pancreas' insulin production even before the physical damage occurs. The results were published Sept. 17 in the Journal of Clinical Investigation.

Ferrets used to study CF-related diabetes

The UI team studied ferrets with CF that were recently developed in the lab of John Engelhardt, Ph.D., professor and head of anatomy and cell biology at the UI Carver College of Medicine.

"We turned to ferrets because studies in humans and mice have been unable to determine the underlying cause of many CF complications, including diabetes," Engelhardt says. "We found that ferrets with CF, just like humans, spontaneously develop diabetes leaving them unable to prevent high blood sugar levels following a meal."

In humans, CF damages the pancreas, which reduces insulin production. The researchers, including lead authors Alicia Olivier, Ph.D., UI assistant professor of pathology, and Yaling Yi and Xingshen Sun, Ph.D., from Engelhardt's lab, found that CF ferrets developed diabetes at 1-2 months of age, the same age the ferrets experienced severe damage to the pancreas.

"This finding fits well with the long-held view that CF-related diabetes stems from physical damage to the pancreas, which limits the amount of insulin the pancreas can produce," says study co-leader Andrew Norris, M.D., Ph.D., associate professor of pediatrics and biochemistry.

Engelhardt and Norris also are members of the Fraternal Order of Eagles Diabetes Research Center at UI.

CF disrupts insulin production from birth

However, studies in newborn CF ferrets led to an interesting twist in the team's findings. The pancreas in newborn ferrets is essentially healthy, so the team expected normal insulin levels and normal blood sugar regulation. Instead, newborn CF ferrets were unable to control spikes in blood sugar. The study showed that this was because the pancreas in these animals did not secrete the appropriate amount of insulin in response to a spike in blood sugar.

Further investigation homed in on groups of cells with the pancreas -- called islets -- as the source of the problem. Islets are the body's insulin-producing factories. The researchers found that islets from newborn CF ferrets did not secrete insulin normally.

"The finding of abnormal sugar-regulated insulin secretion by isolated CF islets demonstrates for the first time that some of the problems that lead to diabetes in CF patients likely reside within cells of the islet," Engelhardt says.

Likening the CF defect in islets to a broken sugar-thermometer, Engelhardt adds, "CF islets fail to adequately sense changes in sugar and this leads to poorly regulated insulin production."

Although the cellular mechanism for this abnormality is not yet known, findings suggest that the chloride channel protein, which is defective in CF, may directly or indirectly control insulin secretion by the islet.

"This indicates that CF causes a second problem which underlies diabetes, separate from pancreatic structural damage," Norris says. "Ultimately, this research will allow us to determine the major root causes of CF-related diabetes, and may help guide development of new therapies and preventative strategies."

Human studies

The new findings already have generated clinical interest in studying the early changes that occur in insulin regulation in infants and young children with CF. Katie Larson Ode, M.D., clinical assistant professor of pediatrics with UI Children's Hospital, and Toni Moran, M.D., at University of Minnesota, have started a clinical trial to study these abnormalities. Additionally, Engelhardt and Norris have teamed up with Aliye Uc, M.D., UI associate professor of pediatrics, to leverage her expertise on pancreatic damage in ongoing studies of animals with CF.

"Although these studies are focused on cystic fibrosis, future insights into how the cystic fibrosis chloride channel functions to regulate insulin secretion may also lead to better treatments for type 2 and other forms of diabetes," Norris concludes.


'/>"/>

Contact: Jennifer Brown
jennifer-l-brown@uiowa.edu
319-356-7124
University of Iowa Health Care
Source:Eurekalert  

Related biology news :

1. New proteins to clear the airways in cystic fibrosis and COPD
2. Cystic fibrosis makes airways more acidic, reduces bacterial killing
3. Johns Hopkins researchers uncover genes at fault for cystic fibrosis-related intestinal obstruction
4. Researchers find critical regulator to tightly control deadly pulmonary fibrosis
5. Liquid glucagon formulation discovered for potential use in artificial pancreas systems
6. Shedding new light on one of diabetes most dangerous complications
7. A mechanism providing clues for research into pancreatic diabetes is described
8. Specific toxic byproduct of heat-processed food may lead to increased body weight and diabetes
9. Drink made from berry wine may provide tasty drug for diabetes
10. Organic study of live pancreatic tissue yields new opportunities for diabetes research
11. 10 new diabetes gene links offer picture of biology underlying disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cystic fibrosis disrupts pancreas two ways in CF-related diabetes
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/9/2016)... in attendance control systems is proud to announce the introduction of fingerprint attendance control ... right employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology: